Quick Answer
Benitec Biopharma Inc. reported Total Assets of $99.59 million for the year ending 2025.
- Benitec Biopharma Inc. showed an increase of +90.8% in Total Assets from 2024 to 2025.
- This data is from Benitec Biopharma Inc.'s annual report (Form 10-K), filed with the SEC on September 22, 2025.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $8.92 million | Q4 2020: $15.51 million | Q1 2021: $13.43 million | Q3 2021: $17.84 million | Q4 2021: $14.01 million | Q1 2022: $10.06 million | Q3 2022: $18.12 million | Q4 2022: $11.91 million | Q1 2023: $8.22 million | Q3 2023: $27.05 million | Q4 2023: $21.35 million | Q1 2024: $15.00 million | Q3 2024: $68.77 million | Q4 2024: $79.07 million | Q1 2025: $105.21 million | Q2 2025: $99.59 million | Q3 2025: $96.03 million | Q4 2025: $190.68 million.
- Over the full 7 years of available data (2019 to 2025), Benitec Biopharma Inc.'s Total Assets has grown by 417.8%.
- Historical annual values: Fiscal year 2025: $99.59 million | Fiscal year 2024: $52.21 million | Fiscal year 2023: $4.46 million | Fiscal year 2022: $5.97 million | Fiscal year 2021: $21.38 million | Fiscal year 2020: $11.59 million | Fiscal year 2019: $19.24 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: